Skip to main content
Clinical Trials/NCT00898261
NCT00898261
Completed
Not Applicable

Genetic Risk Classes in Adult Acute Lymphocytic Leukemia

ECOG-ACRIN Cancer Research Group0 sites137 target enrollmentOctober 26, 2007
ConditionsLeukemia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Leukemia
Sponsor
ECOG-ACRIN Cancer Research Group
Enrollment
137
Primary Endpoint
Comparison of patterns of mRNA expression of BCR/ABL fusion protein in patients with B-lineage acute lymphoblastic leukemia (ALL) vs patients with ALL who lack cytogenetic abnormalities
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

RATIONALE: Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking at gene expression in tissue from patients with acute lymphoblastic leukemia enrolled in clinical trial ECOG-2993.

Detailed Description

OBJECTIVES: * Identify genes involved in specific biologic processes or molecular functions that contribute to the mechanisms by which the BCR/ABL tyrosine kinase induces a leukemic phenotype using RNA banked from patients with BCR/ABL-positive acute lymphoblastic leukemia (ALL) enrolled on ECOG-2993. * Compare patterns of mRNA expression of BCR/ABL fusion protein in patients with B-lineage ALL vs patients with ALL and no cytogenetic abnormalities enrolled on ECOG-2993. * Determine both shared and differing expression patterns in patients with BCR/ABL-positive and cytogenetically negative ALL with respect to achievement of complete remission and duration of disease-free and overall survival. OUTLINE: This is a multicenter study. Total RNA is isolated from stored tissue samples and integrity is verified by reverse transcription-polymerase chain reaction (RT-PCR). cDNA libraries are created from total RNA and gene expression is analyzed via microarray analysis. Genes of interest are further analyzed by flow cytometry and RT-PCR. PROJECTED ACCRUAL: A total of 137 patients will be accrued for this study.

Registry
clinicaltrials.gov
Start Date
October 26, 2007
End Date
July 19, 2012
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
ECOG-ACRIN Cancer Research Group
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Comparison of patterns of mRNA expression of BCR/ABL fusion protein in patients with B-lineage acute lymphoblastic leukemia (ALL) vs patients with ALL who lack cytogenetic abnormalities

Time Frame: 1 month

Shared and differing expression patterns in patients with BCR/ABL-positive and cytogenetically negative ALL with respect to achievement of complete remission and duration of disease-free and overall survival

Time Frame: 1 month

Genes involved in specific biologic processes or molecular functions that contribute to the mechanisms by which the BCR/ABL tyrosine kinase induces a leukemic phenotype

Time Frame: 1 month

Similar Trials